March 2024 tender notification
Te Pātaka Whaioranga - Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 187 KB]
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender, dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of April 2024 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Cinacalcet |
Tab 30 mg; 28 tablet blister pack |
$42.06 |
$25.24 |
Cinacalcet Devatis (Devatis) |
1 July 2024 |
1 December 2024 |
|
Cinacalcet |
Tab 60 mg; 28 tablet blister pack |
$84.12 |
$50.47 |
Cinacalcet Devatis (Devatis) |
1 July 2024 |
1 December 2024 |
|
Erlotinib |
Tab 100 mg; 30 tablet blister pack |
$329.70 |
$280.84 |
Alchemy (Alchemy) |
1 May 2024 |
1 October 2024 |
|
Erlotinib |
Tab 150 mg; 30 tablet blister pack |
$569.70 |
$484.24 |
Alchemy (Alchemy) |
1 May 2024 |
1 October 2024 |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack |
$5.82 |
$4.37 |
Hameln (Max Health) |
1 July 2024 |
1 December 2024 |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack |
$11.49 |
$8.62 |
Hameln (Max Health) |
1 July 2024 |
1 December 2024 |
|
Oxycodone hydrochloride |
Inj 50 mg per ml ampoule; 5 ampoule pack |
$22.92 |
$14.90 |
Hameln (Max Health) |
1 July 2024 |
1 December 2024 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Naloxone hydrochlride |
Inj 400 mcg per ml, 1 ml ampoule; 5 ampoule pack |
$35.26 |
$13.29 |
DBL Naloxone Hydrochloride (Pfizer) |
1 November 2024 |
1 April 2025 |
Hameln (Max Health) |
|
Octreotide Long-Acting |
Inj depot 30 mg prefilled syringe; 1 prefilled syringe pack |
$718.55 |
$670.80 |
Sandostatin LAR (Novartis) |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of Subsidy Change |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Octreotide Long-Acting |
Inj depot 10 mg prefilled syringe; 1 prefilled syringe pack |
$1,152.00 |
$438.40 |
Sandostatin LAR (Novartis) |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
|
Octreotide Long-Acting |
Inj depot 20 mg prefilled syringe; 1 prefilled syringe pack |
$1,539.00 |
$583.70 |
Sandostatin LAR (Novartis) |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Cinacalcet |
Tab 30 mg; 28 tablet blister pack |
$42.06 |
$25.24 |
Cinacalcet Devatis (Devatis) |
5% |
1 July 2024 |
1 December 2024 |
|
Cinacalcet |
Tab 60 mg; 28 tablet blister pack |
$84.12 |
$50.47 |
Cinacalcet Devatis (Devatis) |
5% |
1 July 2024 |
1 December 2024 |
|
Erlotinib |
Tab 100 mg; 30 tablet blister pack |
$329.70 |
$280.84 |
Alchemy (Alchemy) |
5% |
1 May 2024 |
1 October 2024 |
|
Erlotinib |
Tab 150 mg; 30 tablet blister pack |
$569.70 |
$484.24 |
Alchemy (Alchemy) |
5% |
1 May 2024 |
1 October 2024 |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack |
$5.82 |
$4.37 |
Hameln (Max Health) |
5% |
1 July 2024 |
1 December 2024 |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack |
$11.49 |
$8.62 |
Hameln (Max Health) |
5% |
1 July 2024 |
1 December 2024 |
|
Oxycodone hydrochloride |
Inj 50 mg per ml ampoule; 5 ampoule pack |
$22.92 |
$14.90 |
Hameln (Max Health) |
5% |
1 July 2024 |
1 December 2024 |
5. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Carboplatin1 |
Inj 10 mg per ml, 45 ml vial; 1 vial pack |
$45.20 |
$25.73 |
Carboplatin Accord (Accord) |
5% |
1 July 2024 |
1 December 2024 |
Carboplatin Ebewe (Novartis) |
|
Naloxone hydrochlride |
Inj 400 mcg per ml, 1 ml ampoule; 5 ampoule pack |
$35.26 |
$13.29 |
DBL Naloxone Hydrochloride (Pfizer) |
5% |
1 November 2024 |
1 April 2025 |
Hameln (Max Health) |
|
Octreotide |
Inj depot 10 mg prefilled syringe; 1 prefilled syringe pack |
$439.97 |
$438.40 |
Sandostatin LAR (Novartis) |
5% |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
|
Octreotide |
Inj depot 20 mg prefilled syringe; 1 prefilled syringe pack |
$647.03 |
$583.70 |
Sandostatin LAR (Novartis) |
5% |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
|
Octreotide |
Inj depot 30 mg prefilled syringe; 1 prefilled syringe pack |
$718.55 |
$670.80 |
Sandostatin LAR (Novartis) |
5% |
1 July 2024 |
1 December 2024 |
Octreotide Depot Teva (Teva) |
|
1The price and subsidy of carboplatin (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 July 2024. The subsidy of carboplatin inj 1 mg for ECP (Baxter) will be reduced from $0.10 per 1 mg to $0.06 per 1 mg from 1 July 2024 in Section B of the Pharmaceutical Schedule |
||||||||
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical Name |
Line Item |
|---|---|
|
Calcium folinate |
Inj 1 g |
|
Calcium folinate |
Inj 100 mg |
|
Calcium folinate |
Inj 3 mg per ml, 1 ml |
|
Calcium folinate |
Inj 300 mg – 350 mg |
|
Calcium folinate |
Inj 50 mg |
|
Calcium folinate |
Tab 15 mg |
|
Cinacalcet |
Tab 90 mg |
|
Hydrocortisone butyrate |
Milky emulsion 0.1% |
|
Hydrocortisone butyrate |
Oint 0.1% |
|
Hydrocortisone butyrate |
Scalp lotn 0.1% |
|
Lomustine |
Cap 10 mg |
|
Lomustine |
Cap 40 mg |
|
Octreotide (widened access) |
Inj depot 10 mg prefilled syringe |
|
Octreotide (widened access) |
Inj depot 20 mg prefilled syringe |
|
Octreotide (widened access) |
Inj depot 30 mg prefilled syringe |
|
Potassium citrate |
Oral liq 3 mmol per ml |
|
Salbutamol |
Nebuliser soln, 1 mg per ml, 2.5 ml |
|
Salbutamol |
Nebuliser soln, 2 mg per ml, 2.5 ml |
|
Salbutamol with ipratropium bromide |
Nebuliser soln, 2.5 mg 5 mg with ipratropium bromide 0.5 mg per 2.5 ml |
|
Vinorelbine |
Inj 10 mg per ml, 1 ml |
|
Vinorelbine |
Inj 10 mg per ml, 5 ml |
For products included in the 2021/22, 2022/2023 and 2023/24 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.